We are live on ! Find out more
ZVRA icon

Zevra Therapeutics
ZVRA

31 hedge funds and large institutions have $21.7M invested in Zevra Therapeutics in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

19% more funds holding

Funds holding: 26 → 31 (+5)

11% more capital invested

Capital invested by funds: $19.5M → $21.7M (+$2.16M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

Holders
31
Holders Change
+5
Holders Change %
+19.23%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
7
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$146K
2
Victory Capital Management
Victory Capital Management
Texas
+$129K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$64.4K
4
NWM
Northwest Wealth Management
Iowa
+$60.6K
5
MPIA
Mountain Pacific Investment Advisers
Idaho
+$40.1K

Top Sellers

1
AWA
Arete Wealth Advisors
Illinois
-$68.2K
2
VF
Virtu Financial
New York
-$53K
3
Morgan Stanley
Morgan Stanley
New York
-$17.1K
4
ISB
Iowa State Bank
Iowa
-$15.1K
5
SIM
Spark Investment Management
New York
-$14.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
DA
1
DSC Advisors
Illinois
$7.26M – – –
Alyeska Investment Group
2
Alyeska Investment Group
Illinois
$4.02M – – –
AWA
3
Arete Wealth Advisors
Illinois
$3.31M -$68.2K -1,131 -2%
Creative Planning
4
Creative Planning
Kansas
$1.84M – – –
CWG
5
C WorldWide Group
Denmark
$1.76M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.17M +$146K +2,418 +15%
Victory Capital Management
7
Victory Capital Management
Texas
$656K +$129K +2,132 +27%
BlackRock
8
BlackRock
New York
$311K +$5.73K +95 +2%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$273K – – –
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$219K -$4.52K -75 -2%
MC
11
Menta Capital
California
$109K -$3.38K -56 -3%
Morgan Stanley
12
Morgan Stanley
New York
$104K -$17.1K -284 -15%
Northern Trust
13
Northern Trust
Illinois
$93K +$11K +183 +15%
ISB
14
Iowa State Bank
Iowa
$82K -$15.1K -250 -17%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$82K +$4.1K +68 +6%
Wells Fargo
16
Wells Fargo
California
$71K +$25.8K +428 +65%
EAM
17
Evanson Asset Management
California
$69K – – –
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$69K +$64.4K +1,068 New
NWM
19
Northwest Wealth Management
Iowa
$65K +$60.6K +1,004 New
SIM
20
Spark Investment Management
New York
$61K -$14.3K -237 -20%
MPIA
21
Mountain Pacific Investment Advisers
Idaho
$43K +$40.1K +665 New
WCM
22
Wealthcare Capital Management
Virginia
$8K – – –
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$5K +$4.22K +70 +1,000%
AG
24
Advisor Group
Arizona
$4K – – –
UBS Group
25
UBS Group
Switzerland
$3K -$9.17K -152 -76%
1
2

ZVRA Hedge Fund Activity: Q4 2017 in Review

31 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2017, worth a combined $21.7M — up 11% from $19.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ZVRA positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 8 trimmed.

The largest buyer was Vanguard Group, adding an estimated $146K. The largest seller was Arete Wealth Advisors, cutting an estimated $68.2K.

  • 31 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2017, up from 26 in Q3 2017.
  • Funds reported $21.7M of Zevra Therapeutics stock for Q4 2017, up 11% quarter-over-quarter.
  • 7 funds opened new Zevra Therapeutics positions in Q4 2017 and 2 closed out, a net change of +5 holders.
  • The largest Zevra Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $146K added.
  • The largest Zevra Therapeutics seller in Q4 2017 was Arete Wealth Advisors, an estimated $68.2K sold.

Based on aggregated 13F filings for Q4 2017.